InMode

Company Overview

InMode is headquartered in Yokneam, Israel and was founded in 2008, which means the company has been building medical devices for 18 years. The company operates in 80+ and is publicly traded under ticker INMD. Annual revenue is approximately $450M (2024). Publicly traded Israeli medical device company known for Morpheus8 RF microneedling and the BodyTite/FaceTite minimally invasive platforms. Strong in physician-owned med spas. Stock has been volatile, trading around $15 after peaking above $50 in 2021.

The company's product portfolio centers on RFAL (RF-Assisted Lipolysis), Fractional RF Microneedling, DPC (Deep Pulse Contouring), with platforms targeting 4 device categories: rf microneedling, body contouring, skin tightening, minimally invasive. Portfolio breadth matters for buyers because manufacturers with multiple platforms can bundle training, service contracts, and consumable agreements across devices. Single-category manufacturers typically have less negotiating flexibility, though they can offer deeper expertise in their specific domain. When evaluating InMode, the right question is not whether the portfolio is wide or narrow, but whether the specific platform you need is strategically important to the company or a legacy product being phased out.

Manufacturer financial stability is a real consideration for capital equipment buyers. InMode's public market visibility means quarterly financials, analyst coverage, and SEC-filed risk factors are all accessible. For physicians considering a InMode platform, the questions worth asking are warranty term length, parts availability commitments, software update policy, and service response times in your specific region. Manufacturers in financial distress sometimes cut these obligations first, and they rarely announce it publicly. The strongest signal of real manufacturer health is whether they are investing in new product development, acquiring complementary technology, or coasting on existing revenue.

Technology Platform

InMode's core technology stack includes RFAL (RF-Assisted Lipolysis), Fractional RF Microneedling, DPC (Deep Pulse Contouring). Each platform represents distinct R&D investment and targets specific clinical indications. Physicians evaluating InMode devices should understand which technology drives which platform because the mechanism of action varies across the company's product lineup.

The technology portfolio is deeper than a single-platform manufacturer, which matters for practices that want to consolidate device purchases with one vendor for training, service, and consumable efficiency. Platform breadth also signals R&D commitment, though it can stretch engineering and support resources thin when the company expands into too many categories at once.

• RFAL (RF-Assisted Lipolysis)
• Fractional RF Microneedling
• DPC (Deep Pulse Contouring)

Product Lineup

InMode currently produces the devices listed below across 4 categories. Each device links to a full independent review with pricing, clinical evidence, pros and cons, and comparisons against category alternatives.

Market Position

InMode competes across 4 device categories, which positions the company differently in each market segment. In some categories, InMode leads on installed base and brand recognition. In others, the company is the value alternative or the technology challenger. Buyers should evaluate the company category by category rather than treating it as uniformly strong or weak across its entire portfolio.

The competitive set varies by category. In rf microneedling, InMode faces a different competitive landscape than in any other segment. Some categories are dominated by 2-3 incumbents. Others are fragmenting as new entrants push on price or differentiate on clinical evidence. For physicians evaluating InMode platforms, the right question is not whether the company is good or bad in general, but how well its specific platform stacks up against the named competitors in your category of interest.

Strengths and Weaknesses

InMode's strengths typically include manufacturer scale ($450M (2024) in annual revenue), international presence (80+), and a publicly traded structure. Companies with this profile usually have stronger sales infrastructure, better training programs, and more predictable parts and service support than smaller competitors. The technology portfolio (RFAL (RF-Assisted Lipolysis), Fractional RF Microneedling) represents real R&D investment that smaller players can't match.

Weaknesses to weigh: any large manufacturer faces pricing pressure from value-tier competitors, distribution challenges in regions where dealer networks are thin, and the constant risk that a clinical safety signal in one product affects perception of the entire portfolio. Physicians evaluating InMode should look at the specific platform they're considering rather than the parent brand. A strong manufacturer can have weak platforms in specific categories, and a struggling manufacturer can have category-leading products. Brand-level reputation is a starting point, not a substitute for platform-level diligence.

Who Should Consider InMode

InMode fits best for practices that value public market visibility and analyst-tracked financials, want access to platforms across 4 categories, and benefit from international support infrastructure. Practices that prioritize bundled training, multi-device service contracts, or trade-in programs across a manufacturer's portfolio also benefit from larger players like InMode.

The fit is weaker for practices that prioritize the absolute lowest price, want to work with smaller manufacturers that offer more personalized service, or need niche features that only specialist competitors provide. The right manufacturer depends on what your practice values more than the manufacturer itself. Match the company to your priorities, not the other way around.

Risk Factors for Buyers

Every medical device purchase carries manufacturer risk. InMode's risk profile reflects its size ($450M (2024)), history (18 years of operation), and structure (public ownership). Public-company transparency helps in one direction: you can read the quarterly risk factors section in their 10-K and see what management itself considers the biggest threats to the business. Quarterly earnings calls reveal whether the company is meeting analyst expectations, losing market share, or facing margin compression from competitors. Stock price movement is a noisy but useful sentiment indicator.

Specific risks to monitor before signing a purchase contract with InMode: warranty coverage (duration, what is covered, and exclusions), parts and service response times in your region (not the national average), software update policy (are updates included in the maintenance contract or charged separately?), consumable pricing stability (have consumable prices increased by more than 5% annually over the past three years?), and ownership change risk (is the company rumored to be for sale, spinning off a division, or preparing for an IPO or acquisition?). Each of these questions has a real answer that a well-informed buyer can verify through conversations with existing InMode customers in your region.

What to Negotiate with InMode

Capital equipment sales reps have significant pricing flexibility that practice buyers rarely fully capture. The published list price on a InMode platform is almost never the real transaction price. Most deals close at 10-20% below list for single-device purchases and 20-30% below list for multi-device bundles. End-of-quarter and end-of-year timing gives you a real pricing advantage because reps have quota pressure to close before their fiscal period closes. Trade-in programs for older devices can reduce net cost by another 10-20%, though the trade-in valuation is often where manufacturers claw back the discount.

Beyond price, the items worth negotiating with InMode include: extended warranty coverage (ask for 24-36 months instead of the standard 12), applicator or accessory inclusions (always ask for additional applicators, treatment tips, or probes thrown in at no cost), consumable starter packages (enough consumables to cover 60-90 days of typical practice use), training and certification (ensure multiple providers in your practice can be trained without additional fees), marketing support (co-marketing funds, patient education materials, or launch campaign support), and trade-in credit for any existing devices you are replacing. An itemized quote can expose missing scope and contract risk. Compare like-for-like configurations and put every material promise in writing.

InMode Medical Devices: Company and Buyer Guide

InMode medical devices are made by a publicly traded Israeli aesthetics company headquartered in Yokneam, Israel. The company is best known for Morpheus8 RF microneedling and BodyTite and FaceTite minimally invasive contouring platforms, with a strong footprint in physician-owned med spas.

A device purchase is also a manufacturer purchase. You are buying the applicators, clinical workflow, service organization, software relationship, and resale story that come with the platform. InMode has a broad enough lineup to matter to a practice planning beyond one treatment room, but the fit depends on what you want the device to do and who will operate it.

InMode Headquarters and Company Facts

InMode's headquarters are in Yokneam, Israel. That is the direct answer for buyers, prospective employees, and practices trying to understand where the company sits operationally.

InMode was founded in 2008 in Yokneam, Israel, and has 18 years of operating history Device Pulse InMode profile. It sells through an international organization rather than operating as a local equipment reseller with a small product catalog.

InMode operates in 80+ countries Device Pulse InMode profile. That scale can help when a practice needs established training materials, replacement components, or a manufacturer that has lived through more than one aesthetic-device cycle.

Annual revenue is approximately $450M as of 2024 Device Pulse InMode profile. Revenue alone does not tell you whether a local representative will answer the phone when a handpiece fails. It does give buyers a more useful starting point than a brand story built around a single viral treatment.

The company's identity is tightly tied to energy-based aesthetics, especially radiofrequency. That makes InMode easier to evaluate than a manufacturer trying to cover every cosmetic modality under one logo. Its portfolio has a point of view: use RF-based treatments to address skin remodeling, contouring, tightening, and procedures that sit between topical aesthetics and traditional surgery.

For a physician-owned practice, that focus can be useful. One vendor relationship may cover several patient conversations that already overlap in the consultation room. The catch is that each platform has its own staffing, consent, downtime, and revenue model. A device lineup does not create demand by itself.

InMode Devices: Morpheus8, BodyTite, FaceTite, and the Broader Lineup

Morpheus8 is the InMode name most patients recognize. It is an RF microneedling platform used in practices that want a familiar non-surgical skin remodeling treatment with a strong consumer brand attached to it.

Morpheus8 runs $40,000-$60,000 Device Pulse InMode profile. That price places it in a competitive part of the RF microneedling market, where the purchase decision should include more than the base system price. Ask about applicator costs, treatment protocols, training, maintenance, and whether your market has already been saturated with similar offers.

The Morpheus8 review is the better place to assess the specific platform, patient positioning, and treatment workflow. The RF microneedling category gives you a wider view of what else a practice might buy instead.

InMode's lineup extends beyond Morpheus8. The company has four tracked device categories: RF microneedling, body contouring, skin tightening, and minimally invasive treatments. That matters because the best InMode purchase is often connected to an existing practice strength rather than a decision made from a product demo.

BodyTite and FaceTite are the clearest examples. These platforms use RF-assisted lipolysis, often shortened to RFAL, for physicians offering minimally invasive contouring. They sit in a different operational category from a facial RF microneedling treatment performed by an aesthetic provider.

BodyTite is associated with larger-area contouring work. FaceTite is oriented toward smaller facial and neck areas. The appeal is straightforward: a physician may be able to offer a procedure for patients who want more than skin maintenance but are not ready for a traditional surgical route.

That does not make the platforms interchangeable with surgery, and a practice should not market them that way. The clinical result depends on patient selection, provider skill, safety processes, recovery expectations, and how honestly the practice describes the treatment. A patient seeking a surgical-level change may still need surgery.

The distinction changes the buying conversation. Morpheus8 may fit a med spa or dermatology setting looking for a high-recognition skin treatment. BodyTite and FaceTite may make more sense where a physician is already performing procedures and can manage the consultation, anesthesia approach, aftercare, and complication protocols that come with a more invasive offering.

InMode also uses product families and platform architecture that can create room for cross-selling within a practice. That can be an advantage when the team has a coherent aesthetic menu. It can also turn into a costly collection of underused handpieces if the purchase starts with features instead of patient demand.

Start with the patient flow. Which concerns are already walking through the door? Which treatments do you currently refer out? Which procedures can your clinicians perform well and safely? The answers should narrow the field faster than a polished sales presentation.

How InMode Compares in RF Microneedling

The practical comparison is rarely InMode versus no device. It is usually InMode versus another platform, a used platform, or the decision to keep referring treatment demand elsewhere.

Rival Lutronic's Genius RF microneedling platform runs $35,000-$55,000 Device Pulse Lutronic profile. The overlap in price means a buyer cannot dismiss either platform as belonging to a separate budget class.

A comparison should start with the treatment experience and the practice model. Ask how each device fits your existing providers, what training is required, how treatment time affects room turnover, and whether the treatment protocol is credible for the patient concerns you see most often.

The Morpheus8 vs Genius comparison is useful because it keeps the decision focused on two direct competitors rather than treating "RF microneedling" as one generic category. That is where many equipment purchases go sideways. The technology label may match while the treatment workflow, brand recognition, and cost of ownership do not.

InMode has an advantage in consumer awareness around Morpheus8. Awareness can reduce the amount of education needed in a consultation, especially when patients arrive already asking about the treatment by name. It can also create a headache if prospective patients expect results based on celebrity content, edited photography, or a treatment story that bears little resemblance to their candidacy.

A practice wins when it can explain the treatment in plain language and set expectations without talking around the tradeoffs. The device may help fill consultations. The consultation decides whether that attention turns into good clinical fit.

Lutronic's Genius may appeal to practices that prefer its treatment approach or have a different view of the local competitive field. Neither manufacturer gets to decide whether your patient base supports the volume. Your schedule does.

InMode as a Public Company: What INMD's Stock Ride Means for Buyers

InMode trades publicly under the ticker INMD. That gives a buyer access to quarterly financial statements, analyst coverage, earnings discussions, and SEC-filed risk factors. Private manufacturers can be excellent partners, but they do not give you the same view into their financial position.

InMode stock has been volatile, trading around $15 after peaking above $50 in 2021 Device Pulse InMode profile. A volatile stock chart does not tell you whether a Morpheus8 treatment will perform in your market. It does tell you that public investors have reassessed the company's growth story and the aesthetics market around it.

That is worth reading as a buyer, not as a trader. Public filings can reveal how management describes demand, international exposure, inventory, regulatory issues, litigation, competitive pressure, and product concentration. Those are business risks a practice may otherwise discover only after committing capital.

The public-company angle also creates a more disciplined due-diligence process. You can look at the company's disclosures, then ask a local representative questions that map to the real operating risk:

• What does the warranty cover, and what does it exclude?
• Which parts fail most often, and how quickly can they be replaced?
• What software updates are expected during ownership?
• What is the service response process in your market?
• Who provides clinical training after the initial installation?
• What happens when a treatment handpiece needs repair or replacement?

Those questions are not adversarial. They are the questions a serious buyer asks before a platform becomes part of the schedule. If the answers are vague, treat that as information.

InMode has a visible financial record and a large installed base. Those are useful signs, but neither replaces a written service agreement. A practice should evaluate the local service organization with the same care it brings to the device itself.

Who Should Buy InMode

InMode fits practices that want RF-based aesthetic treatments to be a meaningful part of the business, not an occasional add-on sitting in a back room.

Morpheus8 can make sense for a dermatology practice, plastic surgery office, or med spa with patient demand for RF microneedling and a team prepared to sell a course of care with clear expectations. Its consumer recognition is valuable when the practice can convert that interest into appropriate consultations.

BodyTite and FaceTite fit a narrower buyer. They are more relevant for physician-led practices that already have procedural expertise, patient screening systems, and the appetite to manage a minimally invasive treatment pathway. Buying them for a menu graphic is a bad idea.

InMode may also suit a practice that wants several related RF offerings from one manufacturer. Consolidating training, service contacts, and vendor relationships can simplify operations. The benefit disappears if the practice buys more capability than it can schedule.

The wrong buyer is chasing a device because nearby competitors advertise it. A competitor may have a different referral base, physician skill set, payer mix, patient demographic, or marketing budget. Copying their capital purchase is not a strategy.

The better question is whether InMode fills a specific gap in your practice. Can you identify the patients? Can your clinicians deliver the treatment well? Can the practice explain the outcome and recovery without overpromising? Can you support the device after the launch excitement fades?

That is the real test. Morpheus8 may bring patients through the door. BodyTite and FaceTite may expand what a physician can offer. The practice still has to make the economics and clinical workflow work.